|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 171.56 USD | -1.23% |
|
-2.93% | -3.46% |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Capitalization | 303B 292B 275B 246B 434B 26,136B 484B 3,344B 1,239B 10,783B 1,137B 1,114B 47,195B | P/E ratio 2024 * |
38.4x | P/E ratio 2025 * | 23.5x |
|---|---|---|---|---|---|
| Enterprise value | 361B 348B 328B 294B 518B 31,158B 577B 3,986B 1,477B 12,854B 1,356B 1,328B 56,262B | EV / Sales 2024 * |
6.45x | EV / Sales 2025 * | 5.96x |
| Free-Float |
96.39% | Yield 2024 * |
3.63% | Yield 2025 * | 3.8% |
More valuation ratios
* Estimated data
More news
Last Transcript: AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | -1.23% | ||
| 1 week | -2.93% | ||
| Current month | -3.46% | ||
| 1 month | -2.29% | ||
| 3 months | -9.16% | ||
| 6 months | -0.44% | ||
| Current year | -3.46% |
1 week
168.72
174.46
1 month
168.72182.17
Current year
168.72182.17
1 year
153.58207.32
3 years
128.26207.32
5 years
62.55207.32
10 years
45.45207.32
| Director | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 2024-06-30 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 2022-06-22 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 2002-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CHM | Chairman | 71 | 2012-12-31 |
Roxanne Austin
BRD | Director/Board Member | 64 | 2012-12-31 |
William Burnside
BRD | Director/Board Member | 73 | 2012-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 6 M€ | 0.00% | - | |
| 6.85% | 30 M€ | +1.14% | - | |
| 6.26% | 0 M€ | -.--% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| -4.22% | -10.08% | -24.73% | +73.23% | 341B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -1.32% | -0.26% | +2.72% | +22.08% | 206B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -1.35% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.96% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 56.04B 53.89B 50.88B 45.56B 80.24B 4,831B 89.49B 618B 229B 1,993B 210B 206B 8,724B | 59.19B 56.91B 53.73B 48.12B 84.75B 5,103B 94.52B 653B 242B 2,105B 222B 217B 9,214B |
| Net income | 7.63B 7.34B 6.93B 6.2B 10.93B 658B 12.19B 84.16B 31.19B 271B 28.62B 28.03B 1,188B | 12.21B 11.74B 11.08B 9.92B 17.48B 1,052B 19.49B 135B 49.89B 434B 45.78B 44.83B 1,900B |
| Net Debt | 58.25B 56.01B 52.88B 47.35B 83.4B 5,021B 93.01B 642B 238B 2,072B 218B 214B 9,067B | 49.54B 47.64B 44.98B 40.28B 70.94B 4,271B 79.11B 546B 202B 1,762B 186B 182B 7,712B |
More financial data
* Estimated data
Employees
50,000
Sector
Pharmaceuticals
Calendar
2025-01-30
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-17 | 171.56 $ | -1.23% | 7,852,525 |
| 25-01-16 | 173.70 $ | +1.37% | 5,235,975 |
| 25-01-15 | 171.35 $ | -2.39% | 8,048,736 |
| 25-01-14 | 175.55 $ | -0.67% | 4,779,147 |
Delayed Quote Nyse, January 17, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.56USD
Average target price
199.93USD
Spread / Average Target
+16.54%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
